FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286560345> ?p ?o ?g. }

• W4286560345 abstract "Background Idiopathic sudden sensorineural hearing loss (ISSNHL) is common, and defined as a sudden decrease in sensorineural hearing sensitivity of unknown aetiology. Systemic corticosteroids are widely used, however their value remains unclear. Intratympanic injections of corticosteroids have become increasingly common in the treatment of ISSNHL. Objectives To assess the effects of intratympanic corticosteroids in people with ISSNHL. Search methods The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; CENTRAL (2021, Issue 9); PubMed; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials (search date 23 September 2021). Selection criteria We included randomised controlled trials (RCTs) involving people with ISSNHL and follow‐up of over a week. Intratympanic corticosteroids were given as primary or secondary treatment (after failure of systemic therapy). Data collection and analysis We used standard Cochrane methods, including GRADE to assess the certainty of the evidence. Our primary outcome was change in hearing threshold with pure tone audiometry. Secondary outcomes included the proportion of people whose hearing improved, final hearing threshold, speech audiometry, frequency‐specific hearing changes and adverse effects. Main results We included 30 studies, comprising 2133 analysed participants. Some studies had more than two treatment arms and were therefore relevant to several comparisons. Studies investigated intratympanic corticosteroids as either primary (initial) therapy or secondary (rescue) therapy after failure of initial treatment. 1. Intratympanic corticosteroids versus systemic corticosteroids as primary therapy We identified 16 studies (1108 participants). Intratympanic therapy may result in little to no improvement in the change in hearing threshold (mean difference (MD) ‐5.93 dB better, 95% confidence interval (CI) ‐7.61 to ‐4.26; 10 studies; 701 participants; low‐certainty). We found little to no difference in the proportion of participants whose hearing was improved (risk ratio (RR) 1.04, 95% CI 0.97 to 1.12; 14 studies; 972 participants; moderate‐certainty). Intratympanic therapy may result in little to no difference in the final hearing threshold (MD ‐3.31 dB, 95% CI ‐6.16 to ‐0.47; 7 studies; 516 participants; low‐certainty). Intratympanic therapy may increase the number of people who experience vertigo or dizziness (RR 2.53, 95% CI 1.41 to 4.54; 1 study; 250 participants; low‐certainty) and probably increases the number of people with ear pain (RR 15.68, 95% CI 6.22 to 39.49; 2 studies; 289 participants; moderate‐certainty). It also resulted in persistent tympanic membrane perforation (range 0% to 3.9%; 3 studies; 359 participants; very low‐certainty), vertigo/dizziness at the time of injection (1% to 21%, 3 studies; 197 participants; very low‐certainty) and ear pain at the time of injection (10.5% to 27.1%; 2 studies; 289 participants; low‐certainty). 2. Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as primary therapy We identified 10 studies (788 participants). Combined therapy may have a small effect on the change in hearing threshold (MD ‐8.55 dB better, 95% CI ‐12.48 to ‐4.61; 6 studies; 435 participants; low‐certainty). The evidence is very uncertain as to whether combined therapy changes the proportion of participants whose hearing is improved (RR 1.27, 95% CI 1.15 to 1.41; 10 studies; 788 participants; very low‐certainty). Combined therapy may result in slightly lower (more favourable) final hearing thresholds but the evidence is very uncertain, and it is not clear whether the change would be important to patients (MD ‐9.11 dB, 95% CI ‐16.56 to ‐1.67; 3 studies; 194 participants; very low‐certainty). Some adverse effects only occurred in those who received combined therapy. These included persistent tympanic membrane perforation (range 0% to 5.5%; 5 studies; 474 participants; very low‐certainty), vertigo or dizziness at the time of injection (range 0% to 8.1%; 4 studies; 341 participants; very low‐certainty) and ear pain at the time of injection (13.5%; 1 study; 73 participants; very low‐certainty). 3. Intratympanic corticosteroids versus no treatment or placebo as secondary therapy We identified seven studies (279 participants). Intratympanic therapy may have a small effect on the change in hearing threshold (MD ‐9.07 dB better, 95% CI ‐11.47 to ‐6.66; 7 studies; 280 participants; low‐certainty). Intratympanic therapy may result in a much higher proportion of participants whose hearing is improved (RR 5.55, 95% CI 2.89 to 10.68; 6 studies; 232 participants; low‐certainty). Intratympanic therapy may result in lower (more favourable) final hearing thresholds (MD ‐11.09 dB, 95% CI ‐17.46 to ‐4.72; 5 studies; 203 participants; low‐certainty). Some adverse effects only occurred in those who received intratympanic injection. These included persistent tympanic membrane perforation (range 0% to 4.2%; 5 studies; 185 participants; very low‐certainty), vertigo or dizziness at the time of injection (range 6.7% to 33%; 3 studies; 128 participants; very low‐certainty) and ear pain at the time of injection (0%; 1 study; 44 participants; very low‐certainty). 4. Intratympanic plus systemic corticosteroids (combined therapy) versus systemic corticosteroids alone as secondary therapy We identified one study with 76 participants. Change in hearing threshold was not reported. Combined therapy may result in a higher proportion with hearing improvement, but the evidence is very uncertain (RR 2.24, 95% CI 1.10 to 4.55; very low‐certainty). Adverse effects were poorly reported with only data for persistent tympanic membrane perforation (rate 8.1%, very low‐certainty). Authors' conclusions Most of the evidence in this review is low‐ or very low‐certainty, therefore it is likely that further studies may change our conclusions. For primary therapy, intratympanic corticosteroids may have little or no effect compared with systemic corticosteroids. There may be a slight benefit from combined treatment when compared with systemic treatment alone, but the evidence is uncertain. For secondary therapy, there is low‐certainty evidence that intratympanic corticosteroids, when compared to no treatment or placebo, may result in a much higher proportion of participants whose hearing is improved, but may only have a small effect on the change in hearing threshold. It is very uncertain whether there is additional benefit from combined treatment over systemic steroids alone. Although adverse effects were poorly reported, the different risk profiles of intratympanic treatment (including tympanic membrane perforation, pain and dizziness/vertigo) and systemic treatment (for example, blood glucose problems) should be considered when selecting appropriate treatment." @default.
• W4286560345 created "2022-07-22" @default.
• W4286560345 creator A5000377274 @default.
• W4286560345 creator A5002675205 @default.
• W4286560345 creator A5006949060 @default.
• W4286560345 creator A5016955537 @default.
• W4286560345 creator A5029217518 @default.
• W4286560345 creator A5043530829 @default.
• W4286560345 creator A5071426349 @default.
• W4286560345 creator A5073950716 @default.
• W4286560345 creator A5074161644 @default.
• W4286560345 creator A5078644982 @default.
• W4286560345 creator A5088049440 @default.
• W4286560345 date "2022-07-22" @default.
• W4286560345 modified "2023-10-06" @default.
• W4286560345 title "Intratympanic corticosteroids for sudden sensorineural hearing loss" @default.
• W4286560345 cites W1047238016 @default.
• W4286560345 cites W1482236737 @default.
• W4286560345 cites W1495716885 @default.
• W4286560345 cites W1527978848 @default.
• W4286560345 cites W1544662101 @default.
• W4286560345 cites W1595956243 @default.
• W4286560345 cites W1747609093 @default.
• W4286560345 cites W1880624981 @default.
• W4286560345 cites W188339275 @default.
• W4286560345 cites W1906222399 @default.
• W4286560345 cites W1907683961 @default.
• W4286560345 cites W1931030458 @default.
• W4286560345 cites W196391592 @default.
• W4286560345 cites W1964623417 @default.
• W4286560345 cites W1964811039 @default.
• W4286560345 cites W1967137187 @default.
• W4286560345 cites W1969560241 @default.
• W4286560345 cites W1971528716 @default.
• W4286560345 cites W1975059105 @default.
• W4286560345 cites W1977338010 @default.
• W4286560345 cites W1978777163 @default.
• W4286560345 cites W1979791904 @default.
• W4286560345 cites W1981844529 @default.
• W4286560345 cites W1982050307 @default.
• W4286560345 cites W1985425584 @default.
• W4286560345 cites W1986814906 @default.
• W4286560345 cites W1987211690 @default.
• W4286560345 cites W1993572827 @default.
• W4286560345 cites W2000821511 @default.
• W4286560345 cites W2001164177 @default.
• W4286560345 cites W2002125886 @default.
• W4286560345 cites W2003523259 @default.
• W4286560345 cites W2003639917 @default.
• W4286560345 cites W2004304312 @default.
• W4286560345 cites W2006179012 @default.
• W4286560345 cites W2011179976 @default.
• W4286560345 cites W2013957998 @default.
• W4286560345 cites W2016729518 @default.
• W4286560345 cites W2018968507 @default.
• W4286560345 cites W2020910455 @default.
• W4286560345 cites W2030877917 @default.
• W4286560345 cites W2031867507 @default.
• W4286560345 cites W2032060082 @default.
• W4286560345 cites W2032472217 @default.
• W4286560345 cites W2038459406 @default.
• W4286560345 cites W2045144185 @default.
• W4286560345 cites W2050424300 @default.
• W4286560345 cites W2051128881 @default.
• W4286560345 cites W2051245045 @default.
• W4286560345 cites W2055940273 @default.
• W4286560345 cites W2057519639 @default.
• W4286560345 cites W2058303666 @default.
• W4286560345 cites W2062355732 @default.
• W4286560345 cites W2069047687 @default.
• W4286560345 cites W2069842204 @default.
• W4286560345 cites W2070594642 @default.
• W4286560345 cites W2070982799 @default.
• W4286560345 cites W2074185898 @default.
• W4286560345 cites W2074677746 @default.
• W4286560345 cites W2078300056 @default.
• W4286560345 cites W2078923958 @default.
• W4286560345 cites W2081453354 @default.
• W4286560345 cites W2086098850 @default.
• W4286560345 cites W2086529610 @default.
• W4286560345 cites W2089874274 @default.
• W4286560345 cites W2090132603 @default.
• W4286560345 cites W2091206767 @default.
• W4286560345 cites W2092411345 @default.
• W4286560345 cites W2092445322 @default.
• W4286560345 cites W2092969339 @default.
• W4286560345 cites W2092999953 @default.
• W4286560345 cites W2099706261 @default.
• W4286560345 cites W2102136926 @default.
• W4286560345 cites W2106349848 @default.
• W4286560345 cites W2107551931 @default.
• W4286560345 cites W2107723133 @default.
• W4286560345 cites W2109156054 @default.
• W4286560345 cites W2109800298 @default.
• W4286560345 cites W2119443867 @default.
• W4286560345 cites W2125600333 @default.
• W4286560345 cites W2126826184 @default.
• W4286560345 cites W2136833459 @default.
• W4286560345 cites W2137014027 @default.
• W4286560345 cites W2144033928 @default.

• next